Dexamethasone Improves Cancer-Related Fatigue in Advanced Cancer Patients
Dexamethasone is more effective than placebo in reducing cancer-related fatigue (CRF) in patients with advanced cancer.
ASCO 2012
Biochemotherapy Improves Relapse-Free Survival in Patients with High-Risk Melanoma
Biochemotherapy (BCT) demonstrates greater improvement in relapse-free survival (RFS) compared to high-dose interferon (HDI).
Vemurafenib Improves Overall Survival in Patients with Metastatic Melanoma
Vemurafenib improved overall survival (OS) in patients with BRAF600E-mutated metastatic melanoma.
Systemic Corticosteroids Resolve Immune-related AEs in Ipilimumab-treated Metastatic Melanoma Patients
Systemic corticosteroids resolve immune-mediated adverse reactions associated with ipilimumab treatment.
No Superiority Seen Over FOLFOX4 in Resectable Metastatic Colorectal Cancer Compared with FOLFOX7 Followed by FOLFIRI
Dose-dense oxaliplatin therapy followed by an irinotecan-based regimen does not improve outcomes over standard FOLFOX4 chemotherapy for metastatic colorectal cancer patients.
Bevacizumab + Chemo Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
In women with platinum-resistant ovarian cancer, bevacizumab plus chemotherapy doubled progression-free survival (PFS) compared with chemotherapy alone.
Adding Aflibercept to FOLFIRI for mCRC Yields Longer Survival Trend
Despite a high incidence of adverse events, adding aflibercept to FOLFIRI chemotherapy is associated with “a consistent trend” of increased survival among metastatic colorectal cancer patients, regardless of patients’ previous bevacizumab treatment status, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
1p/19q Co-Deletion Key in Anaplastic Oligodendroglioma Chemo
Adding procarbazine, lomustine and vincristine chemotherapy to radiotherapy increases PFS and OS in patients with anaplastic oligodendroglial tumors and represents a new standard of care in those with 1p/19q co-deletions, according to data presented at the 2012 American Society of Clinical Oncology Annual Meeting.
No Survival Benefit with Induction Chemo for Squamous Cell Carcinoma of the Head and Neck
Induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck did not improve OS, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
No OS Benefits with Addition of Perifosine to Capecitabine in mCRC
Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...